Endo K
Department of Nuclear Medicine, Gunma University Hospital.
Kaku Igaku. 1995 Oct;32(10):1125-30.
The most commonly used radionuclides for cancer patients in Japan have been still 67Ga and 201T1 chloride. In addition to the diagnosis of lung cancer and thyroid tumor, 201T1 is recently applied to patients with brain tumor, bone and soft tissue tumor and parathynoid adenoma. Comparing to Nuclear Cardiology and Brain Nuclear Medicine, where many new radiopharmaceuticals have been developed, there are few new drugs in Nuclear Oncology. In other words, new radiopharmaceuticals are expected to be developed for the diagnosis and/or therapy of cancer. In addition to 131I for thyroid cancer, new radiopharmaceuticals such as 111In-octreotide and 99mTc(V)-DMSA have been clinically employed. In spite of strong expectation, radiolabeled monoclonal antibodies have not been clinically used in Japan. However, the technique of humanized antibodies has been established and in U.S.A., 131I-labeled antibodies are reported to be effective for the treatment of malignant lymphoma. 89Sr is useful for the relief of bone pain caused by the bone metastasis. New findings that SPECT of 18F-FDG, a positron emitter, has been revealed to have a great potential in the management of cancer patients, will give a great impact on Nuclear Oncology.
在日本，癌症患者最常用的放射性核素仍是67Ga和201Tl氯化物。除了用于肺癌和甲状腺肿瘤的诊断外，201Tl最近还应用于脑肿瘤、骨与软组织肿瘤以及甲状旁腺腺瘤患者。与已开发出许多新型放射性药物的核心脏病学和脑核医学相比，核肿瘤学领域的新药很少。换句话说，期望开发出新的放射性药物用于癌症的诊断和/或治疗。除了用于甲状腺癌的131I外，111In-奥曲肽和99mTc(V)-二巯基丁二酸等新型放射性药物已在临床上应用。尽管人们寄予厚望，但放射性标记单克隆抗体在日本尚未临床应用。然而，人源化抗体技术已经确立，在美国，131I标记抗体据报道对恶性淋巴瘤的治疗有效。89Sr对缓解骨转移引起的骨痛有用。正电子发射体18F-FDG的SPECT在癌症患者管理中具有巨大潜力这一新发现，将对核肿瘤学产生重大影响。
